Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study

Farinha, Hugo Teixeira; Grass, Fabian; Kefleyesus, Amaniel; Achtari, Chahin; Romain, B.; Montemurro, Michael; Demartines, Nicolas; Hübner, Martin

doi:10.1155/2017/4596176

Cited by 45 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another promising finding in this study is significant ascites control already after the first cycle of intraperitoneal chemotherapy as PIPAC. The positive effect of PIPAC on ascites has already been reported in other studies [ 21 , 48 ] and appears independent from the type of primary tumor and might contribute to the stabilization of the quality of life reported after PIPAC in several clinical studies [ 21 , 45 , 49 ] and patient cohorts [ 48 , 50 , 51 ].…”

Section: Discussionsupporting

confidence: 68%

Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study

Kurtz

Struller

Horvath

et al. 2018

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Introduction Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel drug delivery system with superior pharmacological properties for treating peritoneal metastasis (PM). Safety and efficacy results of PIPAC with cisplatin/doxorubicin or oxaliplatin from a registry cohort are presented. Methods IRB-approved registry study. Retrospective analysis. No predefined inclusion criteria, individual therapeutic recommendation by the interdisciplinary tumor board. Safety assessment with CTCAE 4.0. Histological assessment of tumor response by an independent pathologist using the 4-tied peritoneal regression grading system (PRGS). Mean PRGS and ascites volume were assessed at each PIPAC. Results A total of 142 PIPAC procedures were scheduled in 71 consecutive patients with PM from gastric (n = 26), colorectal (n = 17), hepatobiliary/pancreatic (n = 9), ovarian (n = 6), appendiceal (n = 5) origin, pseudomyxoma peritonei (n = 4), and other tumors (n = 3). Mean age was 58 ± 13 years. Patients were heavily pretreated. Mean PCI was 19 ± 13. Laparoscopic nonaccess rate was 11/142 procedures (7.7%). Mean number of PIPAC/patient was 2. All patients were eligible for safety analysis. There was no procedure-related mortality. There were 2.8% intraoperative and 4.9% postoperative complications. 39 patients underwent more than one PIPAC and were eligible for efficacy analysis, and PRGS could be assessed in 36 of them. In 24 patients (67%), PRGS improved or remained unchanged at PIPAC#2, reflecting tumor regression or stable disease. Ascites was present in 24 patients and diminished significantly under therapy. Median survival was 11.8 months (95% CI: 7.45–16.2 months) from PIPAC#1. Conclusion PIPAC is feasible, safe, and well-tolerated and can induce histological regression in a significant proportion of pretreated PM patients. This trial is registered with NCT03210298.

show abstract

Section: Discussionsupporting

confidence: 68%

Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study

Kurtz

Struller

Horvath

et al. 2018

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…The present findings confirm the previously reported results. As a consequence of low toxicity, encouraging results regarding quality of life and tolerance of the procedure have been described by our group and by others 8 , 9 , 37 .…”

Section: Discussionmentioning

confidence: 59%

“…Surgery typically required 2 trocars for a median duration of 94 (89-108) minutes, whereas median PCI was 10 8 , 9 .…”

Section: Resultsmentioning

confidence: 99%

“…The present analysis on toxicity and inflammatory response includes all consecutive patients operated until April 2016. Feasibility, postoperative outcomes and quality of life of this cohort were reported recently 8 , 9 . The study was approved by the Institutional Review Board (N°2016/0274) and all patients provided written consent for utilization of their data.…”

Section: Methodsmentioning

confidence: 90%

See 1 more Smart Citation

Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy

H¹,

Grass²,

Labgaa³

et al. 2018

J. Cancer

Self Cite

View full text Add to dashboard Cite

Background: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel mode of intraperitoneal (IP) drug delivery claiming high IP tissue concentrations with low systemic uptake. The aim was to study inflammatory response and systemic toxicity after PIPAC.Methods: Retrospective monocentric analysis of a consecutive cohort of PIPAC patients between January 2015 and April 2016. Detailed hematological and biochemical analysis was performed the day before surgery and once daily until discharge. Comparative statistics were performed using Mann-Whitney U test and Wilcoxon signed ranked test.Results: Fourty-two consecutive patients underwent a total of 91 PIPAC procedures. Twenty patients received oxaliplatin and 22 cisplatin+doxorubicin (37 vs. 54 procedures). Creatinine, AST and ALT were not significantly altered after PIPAC (p=0.095, p= p=0.153 and p=0.351) and not different between oxaliplatin and cisplatin+doxorubicin regimens (p=0.371, p=0.251 and p=0.288). C-reactive protein (CRP) and procalcitonin (PCT) increased on post-operative day (POD) 2: ∆max 29±5 mg/L (p<0.001) and ∆max 0.05±0.01 μg/L (p=0.005), respectively. Leucocytes increased at POD 1: ∆max 2.2±0.3 G/L (p<0.001). Albumin decreased at POD 2: ∆max -6.0±0.5 g/L (p<0.001). CRP increase correlated positively with Peritoneal Cancer Index (tumor load) (ρ =0.521, p<0.001).Conclusion: PIPAC was followed by a modest and transitory inflammatory response that was commensurate to the disease extent. No hematological, renal or hepatic toxicity was observed even after repetitive administration.

show abstract

“…Currently, the PIPAC procedure is performed in nearly 30 countries, mostly in Western Europe, in a total of 100 highly specialized treatment centres. 20 For many countries, such as Italy, France and Denmark, implementation of this novel drug delivery technique occurred only within the last 2 years, in a smooth implementation period lasting 3–6 months. Many institutions worldwide are now preparing to undertake their first PIPAC procedure.…”

Section: Introductionmentioning

confidence: 99%

The scientific report from the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures performed in the eastern part of Central Europe

Nowacki

Zegarski

2018

J Int Med Res

View full text Add to dashboard Cite

ObjectiveTo perform a single-centre, detailed analysis of the preparations for the introduction of the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) programme in the eastern part of Central Europe.MethodsThe study analysed the 14-month preparation period prior to the performance of the first PIPAC procedure with respect to: (i) general preparations; (ii) patient referral and qualification; (iii) the first PIPAC procedure; (iv) the 2 weeks following PIPAC programme establishment; and (v) general problematic issues that arose.ResultsThe length of time needed to prepare our institution for the first PIPAC procedure was extremely long compared with other European Union PIPAC centres: 14 months versus a standard 3–6 months of preparation. The longest amount of time (12 months) was required to prepare the required paperwork.ConclusionsA new PIPAC programme was successfully established in the eastern part of Central Europe. The length of time to implement this method was significantly longer because of lengthy bureaucratic processes. These current findings should help new centres, especially in this part of Europe, to establish a PIPAC programme more quickly.

show abstract

Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study

Cited by 45 publications

References 29 publications

Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study

Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study

Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy

The scientific report from the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures performed in the eastern part of Central Europe

Contact Info

Product

Resources

About